Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4885893 | 0.89 | CYP3A4 (0.52) | CYP3A4CYP2C9MCHR1GRM5SMN1; SMN2 | |
| SCHEMBL4886747 | 0.85 | CYP3A4 (0.71) | CYP3A4CYP2C9MCHR1CTSLCTSB | |
| SCHEMBL4884572 | 0.83 | CYP3A4 (0.58) | CYP3A4CYP2C9MCHR1CTSLCTSB | |
| SCHEMBL4885288 | 0.82 | CYP3A4 (0.73) | CYP3A4CYP2C9MCHR1CYP1A2CYP2D6 | |
| SCHEMBL4888544 | 0.81 | CYP3A4 (0.55) | CYP3A4CYP2C9MCHR1CTSLCTSB | |
| SCHEMBL4877737 | 0.77 | RAB9A (0.43) | PPARGKDM4ESMN1; SMN2NPC1RAB9A | |
| SCHEMBL7849956 | 0.77 | PPARG (0.60) | CYP3A4CYP2C9PPARGKDM4ECYP1A2 | |
| SCHEMBL4878917 | 0.75 | CYP3A4 (0.77) | CYP3A4CYP2C9MCHR1CYP1A2CYP2D6 | |
| SCHEMBL4889001 | 0.74 | CYP3A4 (0.72) | CYP3A4CYP2C9MCHR1SMN1; SMN2CYP1A2 | |
| SCHEMBL31166839 | 0.74 | NPC1 (0.47) | CYP2C9MCHR1CTSLCTSBGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| EP-1861095-A1 | DERIVATIVES OF IMIDAZO(1,2-A)PYRIDINE USEFUL AS MEDICAMENTS FOR TREATING GASTROINTESTINAL DISEASES | GLAXO GROUP LIMITED (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006100119-A1 | DERIVATIVES OF IMIDAZO (1,2-A) PYRIDINE USEFUL AS MEDICAMENTS FOR TREATING GASTROINTESTINAL DISEASES | GLAXO GROUP LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | ALPI, PYGL, PPIP5K2 | CYP3A4 215/4885CYP2C9 1357/4885MCHR1 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.